I-Mab Plans Second Listing on Shanghai's STAR Board
publication date: Jul 27, 2021
I-Mab, a Shanghai biotech, announced it is planning to add a listing on the STAR Board of the Shanghai Exchange. The new offering is expected to take place in 2022. In early 2020, I-Mab completed a NASDAQ listing that raised $104 million. The company will also explore a Hong Kong IPO. I-Mab was formed in 2016 when CBC and Tasly Pharma merged two China biopharmas and funded them to promote novel drug discovery. In September 2020, I-Mab out-licensed ex-China rights for its anti-CD47 mAb to AbbVie in a $2 billion agreement. More details....
Stock Symbol: (NSDQ: IMAB)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.